+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

C-X-C Chemokine Receptor Type 4 - Pipeline Review, H1 2019

  • ID: 4772678
  • Drug Pipelines
  • May 2019
  • Region: Global
  • 125 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AdAlta Ltd
  • Biokine Therapeutics Ltd
  • Bristol-Myers Squibb Co
  • FairJourney Biologics SA
  • Harmonic Pharma
  • Polyphor AG
  • MORE
C-X-C Chemokine Receptor Type 4 - Pipeline Review, H1 2019

Summary

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene. It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extracellular ubiquitin, leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. It is involved in hematopoiesis and in cardiac ventricular septum formation. It also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells.

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) pipeline Target constitutes close to 27 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 3, 1, 11 and 1 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Genetic Disorders, Hematological Disorders, Immunology, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Male Health, Ophthalmology, Respiratory and Undisclosed which include indications Multiple Myeloma (Kahler Disease), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Melanoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Breast Cancer, Colon Cancer, Neuroblastoma, Prostate Cancer, Solid Tumor, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Aplastic Anemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Critical Limb Ischemia, Epithelial Ovarian Cancer, Erectile Dysfunction, Gastric Cancer, Glioblastoma Multiforme (GBM), Hematopoietic Stem Cell Transplantation, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Idiopathic Pulmonary Fibrosis, Inflammation, Intimal Hyperplasia, Kidney Fibrosis, Liver Cancer, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Myelodysplastic Syndrome, Myocardial Infarction, Neutropenia, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Primary Immune Deficiency (PID), Recurrent Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Stroke, Thrombocytopenia, Unspecified, Vasomotor Symptoms (Non-Menopausal), Wet (Neovascular / Exudative) Macular Degeneration, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).

The latest report C-X-C Chemokine Receptor Type 4 - Pipeline Review, H1 2019, outlays comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)
  • The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AdAlta Ltd
  • Biokine Therapeutics Ltd
  • Bristol-Myers Squibb Co
  • FairJourney Biologics SA
  • Harmonic Pharma
  • Polyphor AG
  • MORE
Introduction

Report Coverage

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Overview

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Companies Involved in Therapeutics Development

AdAlta Ltd

Ambrx Inc

Biokine Therapeutics Ltd

BioLineRx Ltd

Bristol-Myers Squibb Co

Eli Lilly and Co

FairJourney Biologics SA

GlycoMimetics Inc

Pfizer Inc

Polyphor AG

Tactiva Therapeutics LLC

TaiGen Biotechnology Co Ltd

Upsher-Smith Laboratories Inc

X4 Pharmaceuticals Inc

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Drug Profiles

AD-214 - Drug Profile

AM-3114 - Drug Profile

balixafortide - Drug Profile

BKT-300 - Drug Profile

BL-8040 - Drug Profile

burixafor - Drug Profile

GMI-1359 - Drug Profile

HPH-112 - Drug Profile

hz-515H7 - Drug Profile

LY-2510924 - Drug Profile

mavorixafor - Drug Profile

Monoclonal Antibodies to Antagonize CXCR4 for Unspecified Indication - Drug Profile

Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile

Oncolytic Virus to Antagonize CXCR4 for Oncology - Drug Profile

PF-06747143 - Drug Profile

POL-5551 - Drug Profile

Protein to Agonize CXCR4 for Inflammation - Drug Profile

PTX-9908 - Drug Profile

Q-122 - Drug Profile

Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile

Recombinant Protein to Antagonize CXCR4 for Oncology - Drug Profile

Small Molecule to Antagonize CXCR4 for Oncology - Drug Profile

ulocuplumab - Drug Profile

USL-311 - Drug Profile

X-4P002 - Drug Profile

X-4P003 - Drug Profile

X4-136 - Drug Profile

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Dormant Products

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Discontinued Products

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by AdAlta Ltd, H1 2019

Pipeline by Ambrx Inc, H1 2019

Pipeline by Biokine Therapeutics Ltd, H1 2019

Pipeline by BioLineRx Ltd, H1 2019

Pipeline by Bristol-Myers Squibb Co, H1 2019

Pipeline by Eli Lilly and Co, H1 2019

Pipeline by FairJourney Biologics SA, H1 2019

Pipeline by GlycoMimetics Inc, H1 2019

Pipeline by Harmonic Pharma, H1 2019

Pipeline by Pfizer Inc, H1 2019

Pipeline by Polyphor AG, H1 2019

Pipeline by Que Oncology Inc, H1 2019

Pipeline by Tactiva Therapeutics LLC, H1 2019

Pipeline by TaiGen Biotechnology Co Ltd, H1 2019

Pipeline by Upsher-Smith Laboratories Inc, H1 2019

Pipeline by X4 Pharmaceuticals Inc, H1 2019

Dormant Products, H1 2019

Discontinued Products, H1 2019

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AdAlta Ltd
  • Ambrx Inc
  • Biokine Therapeutics Ltd
  • BioLineRx Ltd
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • FairJourney Biologics SA
  • GlycoMimetics Inc
  • Harmonic Pharma
  • Pfizer Inc
  • Polyphor AG
  • Que Oncology Inc
  • Tactiva Therapeutics LLC
  • TaiGen Biotechnology Co Ltd
  • Upsher-Smith Laboratories Inc
  • X4 Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll